| Quarterly Financials | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 188 | 208 | 190 | 189 | 192 | 237 | 213 | 215 | 251 | 267 | 259 | 223 | 275 | 286 | 270 | 243 | 289 | 327 | 308 | 277 | 350 | 360 | 333 | 309 | 395 | 461 | 420 | 398 | 461 | 504 | 488 | 562 | 717 | 744 | 726 | 711 |
| Expenses | 109 | 125 | 112 | 135 | 114 | 152 | 128 | 141 | 162 | 164 | 159 | 153 | 170 | 175 | 190 | 171 | 189 | 205 | 203 | 184 | 223 | 220 | 210 | 209 | 269 | 309 | 286 | 284 | 297 | 324 | 311 | 403 | 470 | 477 | 477 | 453 |
| EBITDA | 79 | 83 | 78 | 54 | 78 | 86 | 85 | 75 | 88 | 103 | 100 | 70 | 105 | 111 | 81 | 72 | 100 | 122 | 105 | 93 | 127 | 141 | 123 | 100 | 125 | 151 | 134 | 114 | 164 | 180 | 177 | 160 | 248 | 267 | 249 | 258 |
| Operating Profit % | 40 % | 37 % | 39 % | 27 % | 39 % | 34 % | 38 % | 32 % | 34 % | 37 % | 36 % | 28 % | 38 % | 38 % | 28 % | 30 % | 34 % | 37 % | 33 % | 33 % | 35 % | 38 % | 36 % | 31 % | 31 % | 32 % | 32 % | 28 % | 35 % | 35 % | 36 % | 26 % | 34 % | 35 % | 34 % | 36 % |
| Depreciation | 5 | 5 | 6 | 7 | 5 | 5 | 7 | 9 | 7 | 8 | 10 | 11 | 12 | 12 | 13 | 14 | 10 | 11 | 11 | 12 | 15 | 15 | 17 | 18 | 23 | 29 | 30 | 35 | 41 | 42 | 46 | 54 | 76 | 81 | 81 | 77 |
| Interest | 0 | 1 | 0 | 0 | 0 | 0 | 3 | 8 | 7 | 6 | 5 | 4 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 7 | 7 | 3 | 9 | 17 | 16 | 18 | 33 | 60 | 60 | 57 | 54 |
| Profit Before Tax | 73 | 78 | 72 | 48 | 74 | 99 | 77 | 62 | 78 | 92 | 89 | 58 | 95 | 103 | 72 | 62 | 95 | 116 | 99 | 85 | 117 | 131 | 109 | 85 | 101 | 121 | 107 | 76 | 113 | 126 | 116 | 77 | 115 | 129 | 116 | 129 |
| Tax | 11 | 8 | 4 | 1 | 3 | 6 | 3 | 6 | 6 | 7 | 9 | 4 | 11 | 10 | 9 | 5 | 6 | 8 | 9 | 17 | 10 | 12 | 8 | 5 | 8 | 2 | 6 | 14 | 19 | 4 | 14 | -3 | 26 | 33 | 29 | 27 |
| Net Profit | 63 | 69 | 68 | 47 | 71 | 93 | 75 | 56 | 72 | 86 | 80 | 54 | 84 | 93 | 64 | 56 | 89 | 108 | 90 | 68 | 107 | 118 | 101 | 80 | 93 | 119 | 100 | 62 | 94 | 122 | 102 | 80 | 89 | 96 | 87 | 102 |
| EPS in ₹ | 45.64 | 5.02 | 4.95 | 3.43 | 5.15 | 6.75 | 5.43 | 4.06 | 5.18 | 6.20 | 5.83 | 3.93 | 6.11 | 6.74 | 4.62 | 4.13 | 6.56 | 7.93 | 6.64 | 5.03 | 7.86 | 8.71 | 7.41 | 5.91 | 6.96 | 8.84 | 7.49 | 4.81 | 6.97 | 9.08 | 7.55 | 5.22 | 6.11 | 6.73 | 6.16 | 6.90 |
Eris Lifesciences
1,504.30
-15.50
(-1.02%)
Q4 Quarterly Results are out. Check out the updated financials3 days ago
View
Market Cap
20,694.00 Cr
EPS
28.82
PE Ratio
58.33
Dividend Yield
0.49 %
Industry
Healthcare52 Week High
1,593.90
52 Week Low
815.85
PB Ratio
7.19
Debt to Equity
0.76
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from9 analysts
Company News
View All News
Eris Lifesciences Provides FY26 Financial Guidance4 days ago
Eris Lifesciences has released its financial guidance for FY26 in an investor presentation. The company projects revenue to be between ₹2,900-3,050 crore. EBITDA is expected to range from ₹1,070-1,130 crore, with an EBITDA margin of 37%.
Eris Lifesciences Reports Strong Q4 Financial Results4 days ago
Eris Lifesciences has announced its Q4 financial results, showing significant year-over-year growth. The company's EBITDA increased to 2.52 billion rupees from 1.5 billion rupees in the previous year. The EBITDA margin improved to 35.78% from 26.94%. Revenue rose to 7.05 billion rupees from 5.51 billion rupees. Consolidated net profit for Q4 reached 938.4 million rupees, up from 710 million rupees year-over-year and 837.6 million rupees quarter-over-quarter.
Eris Lifesciences: Q4 Profit Surges 31%, EBITDA Margin Expands to 36%4 days ago
Eris Lifesciences reported Q4 FY25 net profit of ₹93.8 crore, up 31.1% YoY. Revenue rose 27.9% to ₹705 crore. EBITDA margin expanded to 36%. FY25 revenue grew 44% to ₹2,894 crore. Company guides FY26 DBF revenue of ₹2,900–3,050 crore and consolidated revenue of ₹3,325–3,500 crore. Aims to reduce net debt to ₹1,800 crore by FY26.
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,683.60 | #1 4,12,373.70 | 35.21 | #1 49,887.20 | 12.06 | #1 9,648 | -18.99 | 40.74 | |
6,483.00 | 1,73,563.40 | 78.53 | 8,184.00 | 0.89 | 1,600 | 23.05 | 63.44 | |
1,484.20 | 1,18,598.30 | 22.74 | 26,520.70 | 14.17 | 4,155 | 30.28 | 47.86 | |
3,174.70 | 1,08,708.70 | 55.70 | 10,785.70 | 11.59 | 1,656 | 10.91 | 43.82 | |
1,230.10 | 1,01,987.10 | #1 18.15 | 28,905.40 | 12.36 | 5,578 | 21.14 | 62.40 | |
2,432.40 | 1,00,636.20 | 50.56 | 10,615.60 | 19.57 | 1,942 | -10.91 | 44.37 | |
908.60 | 90,908.20 | 19.56 | 19,831.50 | 13.82 | 3,831 | -0.19 | 56.78 | |
1,978.90 | 89,879.20 | 27.54 | 20,141.50 | #1 19.94 | 1,936 | #1 112.49 | 44.10 | |
1,197.10 | 69,010.80 | 19.71 | 29,559.20 | 17.55 | 3,169 | -10.04 | 50.83 | |
30,795.00 | 66,181.00 | 46.30 | 6,097.20 | 10.80 | 1,201 | 27.83 | 54.40 |
Forecast
Actual
Growth Rate
Revenue Growth
19.85 %
Net Income Growth
6.12 %
Cash Flow Change
66.59 %
ROE
-26.88 %
ROCE
-14.45 %
EBITDA Margin (Avg.)
6.41 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 398 | 727 | 1,460 | 1,554 | 1,552 | 1,835 | 2,272 | 3,667 | 7,049 |
| Fixed Assets | 65 | 232 | 771 | 761 | 875 | 854 | 918 | 2,568 | 4,328 |
| Current Assets | 237 | 216 | 299 | 582 | 480 | 467 | 627 | 765 | 2,302 |
| Capital Work in Progress | 0 | 0 | 0 | 3 | 4 | 2 | 27 | 22 | 20 |
| Investments | 144 | 303 | 365 | 356 | 78 | 294 | 520 | 37 | 16 |
| Other Assets | 190 | 192 | 324 | 435 | 595 | 685 | 807 | 1,041 | 2,686 |
| Total Liabilities | 398 | 727 | 1,460 | 1,554 | 1,552 | 1,835 | 2,272 | 3,667 | 7,049 |
| Current Liabilities | 71 | 76 | 226 | 306 | 165 | 167 | 200 | 443 | 2,532 |
| Non Current Liabilities | 25 | 60 | 349 | 79 | 91 | 91 | 164 | 1,003 | 1,295 |
| Total Equity | 302 | 591 | 886 | 1,169 | 1,296 | 1,576 | 1,908 | 2,221 | 3,222 |
| Reserve & Surplus | 302 | 553 | 848 | 1,137 | 1,283 | 1,563 | 1,894 | 2,182 | 2,573 |
| Share Capital | 0 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | -2 | 4 | -8 | 8 | -3 | 60 | -30 | 14 | 5 | 38 |
| Investing Activities | -92 | -44 | -185 | -590 | -5 | 123 | -323 | -320 | -975 | -1,828 |
| Operating Activities | 90 | 132 | 200 | 235 | 223 | 271 | 375 | 378 | 292 | 486 |
| Financing Activities | 1 | -84 | -24 | 363 | -221 | -335 | -82 | -45 | 688 | 1,380 |
Share Holding
| % Holding | Jan 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 55.55 % | 54.13 % | 52.69 % | 52.68 % | 52.66 % | 52.66 % | 52.30 % | 52.29 % | 52.70 % | 52.86 % | 52.86 % | 54.91 % | 54.90 % | 54.90 % | 54.88 % | 54.87 % | 54.86 % | 54.85 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 13.20 % | 0.00 % | 14.27 % | 14.59 % | 8.01 % | 8.35 % | 8.43 % |
| DIIs | 10.52 % | 9.25 % | 9.66 % | 9.57 % | 9.99 % | 10.11 % | 10.36 % | 10.38 % | 9.94 % | 10.02 % | 10.28 % | 14.53 % | 13.86 % | 15.63 % | 16.23 % | 18.64 % | 18.06 % | 18.07 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 22.42 % | 23.28 % | 23.23 % | 23.29 % | 23.19 % | 23.14 % | 21.34 % | 21.27 % | 21.45 % | 21.66 % | 22.07 % | 15.47 % | 15.67 % | 14.24 % | 13.53 % | 10.51 % | 9.29 % | 9.16 % |
| Others | 11.51 % | 13.34 % | 14.42 % | 14.46 % | 14.16 % | 14.09 % | 16.01 % | 16.07 % | 15.90 % | 15.46 % | 14.79 % | 1.90 % | 15.57 % | 0.95 % | 0.77 % | 7.96 % | 9.43 % | 9.49 % |
| No of Share Holders | 29,195 | 41,470 | 46,477 | 49,833 | 54,223 | 57,061 | 51,639 | 48,055 | 46,746 | 45,931 | 44,169 | 42,245 | 46,496 | 51,753 | 44,176 | 46,346 | 53,314 | 50,087 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 2.87 | 5.5 | 6.01 | 7.35 | 0.00 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.47 | 0.8 | 1.05 | 0.87 | 0.00 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 19 May 2025 |  Quarterly Result Announcement | NA | 19 May 2025 | 1,402.05 | 1,465.15 |
| 13 Feb 2025 |  Dividend | ₹ 7.35 /share | 13 Feb 2025 | 1,460.10 | 1,301.85 |
| 04 Feb 2025 | Quarterly Result Announcement | NA | 04 Feb 2025 | 1,157.90 | 1,249.75 |
| 25 Oct 2024 | Quarterly Result Announcement | NA | 25 Oct 2024 | 1,329.15 | 1,283.80 |
| 25 Sept 2024 |  Annual General Meeting | NA | 25 Sept 2024 | 1,454.55 | 1,311.75 |
| 25 Sept 2024 | Annual General Meeting | NA | 25 Sept 2024 | 1,119.35 | 1,311.75 |
| 16 Aug 2022 | Dividend | ₹ 7.35 /share | 11 Aug 2022 | 696.65 | 695.05 |
| 06 Aug 2021 | Dividend | ₹ 6.01 /share | 05 Aug 2021 | 742.15 | 747.90 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
4 days ago
4 days agoRevision In Outcome Of Board Meeting4 days ago
4 days agoFinancial Results For Quarter And Year Ended March 31 20254 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Investor Presentation4 days ago
4 days agoBoard Meeting Outcome for Outcome Of Board Meeting4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation8 days ago
8 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation10 days ago
10 days agoBoard Meeting Intimation for Consideration And Approval Of The Standalone And Consolidated Audited Financial Results Of The Company For The Quarter And Financial Year Ended March 31 202510 days ago
10 days agoUpdate On Credit Rating Of Eris Therapeutics LimitedMay 09, 2025
May 09, 2025Announcement under Regulation 30 (LODR)-Credit RatingMay 09, 2025
May 09, 2025 Announcement Under Regulation 30 (LODR)-Credit Rating Of Eris Therapeutics LimitedMay 06, 2025
May 06, 2025Announcement under Regulation 30 (LODR)-Credit RatingMay 06, 2025
May 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 05, 2025
May 05, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 29, 2025
Apr 29, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSApr 24, 2025
Apr 24, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 05, 2025
Apr 05, 2025Corporate GuaranteeMar 31, 2025
Mar 31, 2025Closure of Trading WindowMar 26, 2025
Mar 26, 2025Clarification With Respect To Increase In VolumeMar 21, 2025
Mar 21, 2025Clarification sought from Eris Lifesciences LtdMar 21, 2025
Mar 21, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 19, 2025
Mar 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 07, 2025
Mar 07, 2025Announcement Under Regulation 30 - Sale Of SubsidiariesMar 06, 2025
Mar 06, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMar 06, 2025
Mar 06, 2025Announcement Under Regulation 30 - Update On Acquisition Of 30% Equity Stake In Levim Lifetech Private LimitedFeb 27, 2025
Feb 27, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 24, 2025
Feb 24, 2025Announcement Under Regulation 30 - Redemption Of 43750 8% Secured Unlisted Redeemable Non-Convertible DebenturesFeb 21, 2025
Feb 21, 2025Announcement Under Regulation 30 - Availing Credit FacilitiesFeb 21, 2025
Feb 21, 2025Corporate GuaranteeFeb 19, 2025
Feb 19, 2025Corporate PresentationFeb 19, 2025
Feb 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 11, 2025
Feb 11, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 11, 2025
Feb 11, 2025Corporate Action-Board approves DividendFeb 07, 2025
Feb 07, 2025Board Meeting Outcome for Declaration Of Interim DividendFeb 07, 2025
Feb 07, 2025Intimation Under Regulation 42 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Revision In Record DateFeb 05, 2025
Feb 05, 2025Board To Consider Interim Dividend - Record DateFeb 04, 2025
Feb 04, 2025Closure of Trading WindowFeb 04, 2025
Feb 04, 2025Corporate Action-Board to consider DividendFeb 04, 2025
Feb 04, 2025Board Meeting Intimation for The Consideration Of The Declaration Of An Interim Dividend For The Financial Year 2024-25.Feb 04, 2025
Feb 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 04, 2025
Feb 04, 2025Integrated Filing (Financial)Feb 04, 2025
Feb 04, 2025Announcement under Regulation 30 (LODR)-Investor PresentationFeb 04, 2025
Feb 04, 2025Financial Results For The Quarter And Nine Months Ended December 31 2024Feb 04, 2025
Feb 04, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held On February 04 2025Feb 04, 2025
Feb 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 29, 2025
Jan 29, 2025Board Meeting Intimation for Consideration And Approval Of Standalone And Consolidated Unaudited Financial Results For The Quarter & Nine Months Ended 31 December 2024.Jan 29, 2025
Jan 29, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 20, 2025
Jan 20, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSDec 09, 2024
Dec 09, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 05, 2024
Dec 05, 2024Technical Indicators
RSI(14)
Neutral 60.94
ATR(14)
Less Volatile 76.66
STOCH(9,6)
Neutral 66.03
STOCH RSI(14)
Neutral 69.27
MACD(12,26)
Bullish 0.14
ADX(14)
Weak Trend 11.92
UO(9)
Bearish 59.28
ROC(12)
Uptrend And Accelerating 4.17
WillR(14)
Overbought -15.50
About Eris Lifesciences
Eris Lifesciences Limited is an Indian company that manufactures and markets pharmaceutical products. Founded in 2007, the company operates a manufacturing plant in Guwahati, Assam. Eris focuses on chronic, sub-chronic, and acute therapeutic areas, including cardiovascular, anti-diabetics, vitamins, gastroenterology, and anti-infective. The company has a portfolio of 112 Mother Brands and a distribution network of 22 sales depots, 2,059 stockists, and over 500,000 retail chemists. Eris has expanded through acquisitions and launches of new divisions. It has five wholly-owned subsidiaries and has acquired various brands and businesses in recent years, including dermatology and cosmetology brands. The company also produces human insulin and has entered the anti-thrombotics segment.
Listing Date
29 Jun, 2017(7 Years,
25 days)
Website
Chairperson NameAmit Indubhushan Bakshi
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
